Clinical Trial Update: Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) [Phase 1]

View source ↗

Summary

Chugai Pharmaceutical’s RAY121 is being studied in a Phase 1b trial (RAINBOW) across several immunological diseases, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antiphospholipid Syndrome
• Behçet Disease
• Bullous Pemphigoid
• Dermatomyositis
• Immune Thrombocytopenia
• Immune-mediated Necrotizing Myopathy

Drugs mentioned

• RAY121

Snippet

Sponsor: Chugai Pharmaceutical | Conditions: Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP) | Phase 1 | Status: RECRUITING